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Abstract 
Protein palmitoylation plays an important role in the function, trafficking and 
localization of many membrane-associated proteins, including the oncogenic Ras 
proteins1,2. Acyl protein thioesterase (APT) enzymes – APT1 and APT2 – are 
homologous enzymes (68% identity) that are thought to catalyze depalmitoylation of 
proteins involved in key cellular processes. Although, very little is known about their 
substrate specificities or regulation, recent studies have discovered two small molecule 
inhibitors – ML348 and ML349 – that are selective towards APT1 and APT2 
respectively3. We hypothesized that by switching certain key residues between APT1 
and APT2, we will be able to reverse the ligand selectivity of the two isoforms. Thus, 
we characterized the kinetics of the APT mutants with isoform-specific inhibitors, and 
identified key residues, Ile75 in APT1 and Pro86 in APT2, in a loop region that likely 
plays an important role in switching ligand and probably endogenous substrate 
specificity. We have also synthesized and characterized APT2 inhibitor derivatives to 
find better inhibitors of APT enzymes, which can help elucidate the environment of the 
substrate-binding pocket. Future directions of this project include utilizing APT isoform-
selective inhibitors to identify the native substrates of APT enzymes in order to 
understand their role in regulation.  
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Introduction 
 Protein S-palmitoylation is the dynamic, post-translational modification in which 
fatty acids are added to proteins through reversible cysteine thioester linkages. The 
addition of this hydrophobic moiety helps anchor soluble proteins to cell membranes and 
endomembranes such as the endoplasmic reticulum (ER) and Golgi membranes. 
Therefore, palmitoylation plays critical roles in the function, trafficking and localization 
of various peripheral membrane proteins4,5.  
The reversibility of this process involves cycles of fatty acid addition by DHHC 
protein acyltransferases (PATs) and fatty acid hydrolysis by depalmitoylating enzymes 
such as acyl-protein thioesterases (APTs).  
The PATs involved in this process 
are characterized by the DHHC catalytic 
motif, which is named after the conserved 
catalytic Asp-His-His-Cys sequence located 
in a cysteine-rich region. The catalytic 
mechanism involves first, autoacylation at 
the DHHC cysteine using an acyl-CoA 
donor, and then the transfer of the fatty acid 
onto the substrate protein6. To date, 23 
DHHC proteins have been identified in 
humans, suggesting divergence in substrate 
specificity, activity or regulation7. This is 
supported by the observation that sequence 
conservation in PATs is limited to the 51-
amino acid DHHC domain, whereas the 
Figure 1: Dynamic S-palmitoylation cycles 
of certain palmitoylated proteins between the 
plasma membrane and endomembranes such 
as the Golgi. Thioesterases hydrolyze the 
fatty acid chain from the protein, thus 
abrogating the association of the protein to 
the membrane. The protein dissociates into 
the cytosol, but can be re-palmitoylated by 
DHHC palmitoyl transferases in the Golgi, 
thus allowing the protein to be recycled back 
to the membrane.  
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amino- and carboxy-terminal domains are more variable and are proposed to contain 
domains determining protein-protein interactions and substrate binding5.  
 In contrast, very few proteins have been conclusively identified as 
depalmitoylating enzymes, two of which are the acyl-protein thioesterases APT1 and 
APT2. In some of the literature, APT1 and APT2 are also identified as 
lysophospholipases LYPLA1 and LYPLA2 as they were first discovered due to their 
ability to hydrolyze various lysophospholipids8. However, they were later shown to have 
much higher affinity and hydrolytic efficiency against acylated proteins, and were thus 
renamed acyl-protein thioesterases9. APT1 and APT2 belong to the alpha/beta serine 
hydrolase family, containing the conserved Ser-His-Asp catalytic triad, in which the 
catalytic serine acts as a nucleophile to covalently attack the thioester linkage of the 
acyl-protein substrate, forming a transient covalent acyl-intermediate with the fatty acid 
to be removed10.  
Although over 400 palmitoylated proteins have been annotated in humans 
through proteomic studies11,12, most of these palmitoylated proteins are relatively stable, 
suggesting that dynamic palmitoylation is not a general phenomenon, but rather specific 
to certain regulatory pathways11. Several of these pathways are implicated in various 
cancers, thus making dynamic palmitoylation an attractive area of research for potential 
therapies. For instance, the oncogenic GTPases H-Ras and N-Ras require attachment to 
the cell membrane to induce cell transformation, and both undergo cycles of 
palmitoylation and depalmitoylation that dictates their localization between the plasma 
membrane, and ER and Golgi membranes depending on their palmitoylation states2. 
Importantly, these pathways are likely regulated through different means, since H-Ras 
subcellular localization is affected by APT1 overexpression, whereas N-Ras subcellular 
localization is not1, thus highlighting the importance of developing methods to 
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selectively study specific palmitoylating or depalmitoylating enzymes to establish their 
specific signaling pathways. 
Although APT1 and APT2 are both very similar proteins (68% sequence 
identity), these two enzymes are likely to have non-redundant functions. For instance, 
growth-associated protein-43 (GAP-43) is deacylated by APT2 but not APT113, whereas 
calcium-activated potassium (BK) channels are deacylated by APT1 but not APT214. 
Thus, the development of isoform-selective inhibitors is necessary in order to isolate the 
specific downstream targets of APT1 and APT2. A previous high-throughput screen of 
APT1 and APT2 against a NIH library of 315,004 compounds yielded two promising 
isoform-selective inhibitors - ML348 and ML349 - for APT1 and APT2 respectively3. 
These compounds are potentially useful tools to probe the specificities of APT1 and 
APT2. In this thesis project, we used these compounds to probe the selectivities of point 
mutants of APT1 and APT2 to identify structures in the active site that confer substrate 
selectivity. We then synthesized and characterized various derivatives of ML349 to 
further probe the active site of APT2. We hope that these results will lay the foundation 
for future studies characterizing the substrate specificities of APT1 and APT2, in the 
hopes of developing better inhibitors. 
 
 
 
Figure 2: Structures of the APT1-selective inhibitor (ML348) and APT2-selective inhibitor (ML349) 
and their Ki values for APT1 and APT2. 
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Materials and Methods 
1. Bacterial transformation and protein purification 
 
  
Figure 3: Pictorial depiction of the procedure for bacterial transformation and creation of glycerol stocks 
for all APT1 and APT2 variants.  
BL21 chemically competent cells were incubated with 2 µL of plasmid DNA 
containing the gene of interest for 30 min on ice. Heat shock was applied at 42°C for 15 
seconds, and then cooled on ice for 5 min. 200 µL of SOC media was added, and the 
mixture was then shaken for 60 min at 37°C. The cells were then plated onto an agar 
plate containing carbenecillin to select for successfully incorporated plasmids, incubated 
upside down overnight at 37°C, and subsequently stored at 4°C. A single colony was 
then selected from the agar plate and grown overnight in 5 mL of TB media (13.3g/L 
yeast extract, 26.7g/L tryptone, 4.4ml/L glycerol) in a mini culture tube at 37°C while 
shaking continuously. 500 µL of the mini culture was then added to 500 µL of 100% 
glycerol and stored at -80°C for use as glycerol stocks. 
 Protein growth was initiated by selecting cells from glycerol stocks and growing 
them at 37°C, first in a 10 mL miniculture overnight, and then in 1L TB media, while 
shaking continuously. Once an optical density of 0.5 at 600nm was achieved, protein 
expression was induced by addition of 1mM IPTG and the cells were allowed to grow 
for overnight at room temperature while shaking continuously.  
BL21 cells 
plasmid Heat shock 42°C	  for	  15s 
200uL SOC 
Shake 37°C	  for	  1hr 
Agar plate 
+ carbenecillin 
Incubate 37°C	  overnight 
Glycerol stock 
Store at -80°C 
500uL bacteria 
+ 
500 uL glycerol 
Select colony 37°C	  overnight 
	   6	  
 Cells were harvested by centrifugation at 5,000g for 5 min. The pellets were then 
resuspended in lysis buffer (150mM NaCl, 10% glycerol, 50mM HEPES, pH 7.5) and 
sonicated at 4°C. The resultant cell debris was further centrifuged at 12,000g for 30 min. 
The supernatant was mixed with cobalt resin, rotated end over end on at 4°C for 15 min 
and centrifuged at 2,000 rpm for 4 min. The resin-containing pellet was washed 3 times 
in wash buffer (150mM NaCl, 50mM HEPES, 1mM imidazole, pH 7.5), and the His-
tagged protein of interest was eluted 6 times with elution buffer (150mM NaCl, 50mM 
HEPES, 50mM imidazole, pH 7.5). Elution fractions containing the overexpressed 
protein were identified using the DC Protein Assay (Bio-Rad), pooled together and 
dialyzed 3 times in 1L dialysis buffer (elution buffer minus imidazole) at 4°C. Protein 
concentration was then determined using the DC Protein Assay, and protein was stored 
in 25% glycerol at -80°C. 
 
2. Steady-state resorufin acetate hydrolysis assay 
Figure 4: The molecular structures of resorufin acetate and its hydrolyzed form as catalyzed by APT1 and 
2 is shown, along with the fluorescence excitation and emission wavelengths of each structure.  
Resorufin acetate (ResOAc) was used as a substrate analog to measure the steady 
state reaction velocities of APT1 and APT2. The acetyl group of ResOAC is hydrolyzed 
by APTs, producing the fluorescent Res- product which has distinct fluorescent 
properties compared to substrate ResOAC that we can measure using a Tecan F500 
microplate reader equipped with excitation and emission filters λex = 535(25)nm, λem = 
590(20)nm respectively. Thus, the catalytic rate of APTs can be assayed by measuring 
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the rate of production of fluorescent Res- over time. In order to account for spontaneous 
hydrolysis of ResOAC by water or non-active site residues of APTs, WT APT1 and 2 
were assayed alongside catalytic dead mutants APT1-S119A or APT2-S122A 
respectively. 
Measuring substrate dependence (Km): Reaction buffer was prepared using 1X 
PBS with 0.01% pluronic adjusted to pH 6.5 using HCl. ResOAc was diluted with 
DMSO to various 20X concentrations ranging from 1.18 µM to 140 µM.  Active and 
catalytic dead enzymes were diluted with reaction buffer to 10.526 nM. The reaction 
was initiated by adding 95 µL of 10.526 nM enzyme to 5 µL of 20X ResOAc of various 
concentrations in a clear, flat-bottomed, 96 well plate (Final concentration: 10nM 
enzyme, 5% DMSO, 1X ResOAc). Fluorescence intensity was then measured using a 
TECAN infinite f500 microplate reader at regular time intervals (λex = 535(25)nm, λem = 
590(20)nm). At least 4 technical replicates and 2 biological replicates were performed 
for each concentration of ResOAc. Fluorescence intensities from the catalytic dead 
enzymes were subtracted from that of the active enzyme to account for background 
fluorescence. Adjusted fluorescence intensity was then plotted against time and averaged 
across replicates to obtain v0 (initial rate of reaction) from the slope of the linear portion 
of the curves. v0 was then plotted against [ResOAc] and fitted to the Michaelis-Menton 
equation, as shown in Equation 1, using Prism or the solver function in Excel to obtain 
the Km.  
                                               v! = !!"#[!]!!![!]                       Equation 1 
Measuring inhibitor dose-response (IC50 and Ki): Reaction buffer was prepared 
as described in the substrate dependence assay above. Inhibitors were diluted with 
DMSO to various concentrations at 48.421X final concentration. Active and catalytic 
dead enzymes were diluted to 10.76nM concentration using reaction buffer. For each 
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inhibitor concentration, 10uL of inhibitor was incubated with 450uL of 10.76nM 
enzyme for 30 minutes. The reaction was initiated by adding 95uL of the enzyme-
inhibitor mix to 5uL of 1mM ResOAc in a clear, flat-bottomed, 96-well plate (Final 
concentration: 10nM enzyme, 7.06% DMSO, 50uM ResOAc, 1X inhibitor). 4 technical 
replicates and 2 biological replicates were performed for each concentration of inhibitor. 
Fluorescence intensity and v0 was obtained as described in the substrate-dependence 
assay above. v0 was then plotted against inhibitor concentration and fitted to the four 
parameter logistic equation (Equation 2) shown below using Prism or the solver function 
in Excel to obtain the IC50. Ki was then calculated using the Cheng-Prusoff equation 
(Equation 3)15. 
          v!!"# I = lim ! →! v!!"# + !"#$!!!" !"#!"!"! ! !"#$$                        Equation 2 𝐾! = !"!"!! [!]!!                                              Equation 3 
3. Thermal shift assay 
  Protein and dye concentrations for the ThermoFluor assay were first optimized 
for APT1 and APT2, and determined to be 0.2mg/mL protein and 0.2mM 
Anilinonaphthalene-8-sulfonic acid (1,8-ANS) [AnaSpec AS-81525]. Inhibitors to be 
tested were dissolved in 100% DMSO to create differing stock concentrations (5.00mM, 
3.33mM, 2.22mM, 1.48mM, 0.99mM, 0mM).  
For the assay, master mixes were created by adding 1.5uL of stock inhibitors to 
1uL of 10mM 1,8-ANS and 47.5uL of 0.2105mg/mL protein in 1X PBS (Final 
concentrations: [I]=0-150uM, [1,8-ANS]=0.2mM, [protein]=0.2mg/mL, [DMSO]=5%). 
10uL of each master mix was aliquot into a 384-well plate [Axygen PCR-384-55-BK] 
with 4 replicates. 3.2uL of silicone oil [Aldrich 378321] was added to prevent 
evaporation. The plate was centrifuged at 1000rpm for 1 min. The thermal shift 
measurements were then performed using a ThermoFluor instrument (Johnson & 
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Johnson Pharmaceutical Research and Development, L.L.C) using continuous ramping 
mode from 25ᵒC to 90ᵒC in increments of 1ᵒC, holding 1 minute at each temperature. 
Data was analyzed using ThermoFluor++ version 1.3.7 software to obtain melting 
temperature, Tm and extreme outliers were omitted.  
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Results and Discussion 
1. Characterizing APT1 & 2 Mutants: Selectivity determinants 
Individual contributions. I would first like to acknowledge and thank the members 
of the Martin Lab who have made significant contributions towards this portion of my 
thesis project. Although I helped purify some of the enzymes used, Christina Rodriguez, 
Laura Rodriguez and Michael Won performed most of the bacterial transformations and 
protein purifications to obtain WT and mutant APTs for study. Michael Won and Dr. 
Dahvid Davda provided much advice and direction for this project, and aided with the 
data analysis and generation of figures. Dr Dahvid Davda also worked on obtaining the 
crystal structures of APT1 and APT2 and generating figures for this thesis. Primarily, 
my principal investigator, Dr. Brent Martin, conceived the main idea for this project, 
provided funding and gave direction on the experiments that were conducted. My role 
was to optimize the conditions for the assays, perform the substrate-dependence and 
dose-response assays, perform initial analysis of the data, and write up this chapter.  
Background. In order to elucidate the mechanism behind the substrate specificity 
of APT1 and APT2, other members in our lab have previously crystallized and obtained 
the structures of APT1 and APT2 bound to their isoform specific inhibitors, ML348 and 
ML349 respectively. Upon examining the protein-inhibitor interactions in the resulting 
protein structures, it was observed that several highly conserved residues that were 
located in homologous positions in both proteins were different between APT1 and 
APT2. These residues appeared to interact differently with ML348 and ML349, and 
were thus hypothesized to contribute to inhibitor specificity. These residue pairs are as 
follow: I75APT1/L78APT2, Q83APT1/P86APT2, R149APT1/H152APT2 and L176APT1/M178APT2.  
In order to test this hypothesis, mutant forms of APT1 and 2 were made such that 
the homologous residues described above were switched between the two isoforms and 
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tested for substrate selectivity using ML348 (APT1-WT selective) and ML349 (APT2-
WT selective). Several orthogonal methods were used to confirm our hypothesis, 
including drug target residency time assays, but within the context of this thesis I will 
only discuss the results of the two assays which I was involved in: the steady state 
hydrolysis of the ResOAc substrate analog assay and the thermal stability assay.  
Results & Discussion. We first assayed the steady-state rate of hydrolysis of 
ResOAc by WT and mutant APT1 and 2 in order to ensure that the point mutations did 
not significantly alter the activities of the enzyme. As shown in Figures 5B and C below, 
all the mutants did not show significantly different Km values towards ResOAc as 
compared to WT. This is important, as Km values of the enzymes will be used in later 
calculations to determine the affinity of the enzymes towards inhibitors15, Ki, and we 
want to ensure that any observed difference in Ki values is due to different enzyme-
inhibitor interactions, and not altered enzyme-substrate interactions.  
No significant difference was observed in Vmax and kcat among APT1-WT and its 
mutants, but surprisingly Vmax and kcat values were about 4 fold higher in all of the APT2 
mutants compared to the WT. This may indicate that APT2 mutants are more efficient at 
turning over ResOAc or clearing the active site once the reaction is complete. 
Nevertheless, since Vmax and kcat are not involved in calculating the Ki of inhibitors, this 
result will not influence our later experiments.  
Inhibitor dose-dependence experiments were then performed on all the APT1 and 
2 WT and mutant enzymes against ML348 (APT1-selective) and ML349 (APT2-
selective) and IC50 and Ki values were calculated from the data shown in Figure 5B-G. 
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Figure 5: Results of the kinetic characterization of APT1 & 2 WT and mutant enzymes with the ResOAc 
substrate analog. (A) Fluorescent ResOAc was used as a substrate analog to assay the affinities of WT and 
mutant APT1 & 2 for ML348 and ML349. (B) & (C): Substrate-dependence of APT1-WT and its mutants, 
and APT2-WT and its mutants respectively against ResOAc. (D) & (E) Dose-dependent inhibition curves 
of ML348 towards APT1 and its mutants, and APT2 and its mutants respectively. (F) & (G) Dose-
dependent inhibition of ML349 towards APT1 and its mutants, and APT2 and its mutants respectively. 
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Among the APT1 point mutants assayed, only the I75L substitution showed 
reversion to APT2-like behavior as it lost considerable affinity for ML348 (~10 fold 
decrease in Ki), as seen in Figure 5D, but gained sensitivity towards ML349 (Ki = 218 
nM) close to that observed in APT2-WT, as shown in Figure 5E. 
As for the APT2 point mutants, only the P86Q substitution gained any detectable 
affinity towards ML348 (Ki = 3090 nM), and even then its affinity is 10 fold higher than 
that of APT1 wild type, as seen in Figure 5F. However, two of the APT2 mutants, P86Q 
and H152R, drastically lost affinity for ML349, with the P86Q mutant being completely 
unable to bind ML349, as shown in Figure 5G. These numerical results are tabulated in 
Table 1 below.  
Interestingly, though APT1-I75L showed reversion, APT2-L51I did not. The same 
was observed with the APT2-P86Q reversion, and the APT1-Q83P, which did not revert. 
This implies that perhaps more than one residue is involved in coordinating ligand 
specificity in the active site.  
Enzyme ResOAc 
Km (µM) 
ResOAc 
Vmax (Fl/s) 
ML348 
Ki (nM) 
ML349 
Ki (nM) 
APT1 14.99 ± 2.075 37.01 ± 1.399 300 >30 
APT1-I75L 23.33 ± 3.676 40.41 ± 2.022 3147 218 
APT1-Q83P 27.81 ± 1.274 65.93 ± 1.016 361 >30 
APT1-L176M 76.94 ± 8.408 60.09 ± 3.245 354 >30 
APT2 17.91 ± 2.562 27.90 ± 1.220 >30 230 
APT2-L78I 19.35 ± 1.392 111.9 ± 2.396 >30 156 
APT2-P86Q 18.71 ± 0.651 84.72 ± 0.873 3090 >30 
APT2-M178L 32.35 ± 1.739 106.6 ± 2.046 >30 122 
APT2-H152R 30.48 ± 1.211 111.6 ± 1.550 2930 5350 
Table 1. Summary of the Km and Vmax of the APT1 and 2 enzymes and their point mutants, along with 
their Ki values towards ML348 and ML349. 
In order to validate the kinetic results observed with the APT1-I75L and APT2-
P86Q, we performed thermal stability measurements to determine the melting 
temperature, Tm of the wild type and mutant enzymes.	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Figure 6: Results of the thermal shift assays characterizing the Tm of APT1, APT1-I75L, APT2 and 
APT2-P86Q when (A) preincubated with ML348 or when (B) preincubated with ML349.  
The thermal shift assay supports our previous findings that APT1-I75L and 
APT2-P86Q show inversion of selectivity. Both APT1-I75L and APT2-P86Q display 
intermediate Tm phenotypes between APT1 and APT2 when bound with either ML348 
or ML349 as shown in Figure 6A and B. This suggests that with APT1, the I75L 
mutation reduces thermal stabilization with ML348, while promoting stabilizing 
interactions with ML349. At the same time, with APT2, the P86Q mutation promotes 
stabilizing interactions with ML348 while reducing thermal stabilization with ML349. 
However, the Tm shifts observed with both point mutants are not very large (< 2°C), so it 
is difficult to make conclusions with strong confidence. There are likely other factors 
besides thermal stabilization that contributes to the inversion observed in the steady-
state kinetic assays.  
 It is difficult to define how single point mutations can cause inversion in 
substrate selectivity of APT1 and APT2. Mapping the I75/L78 and Q83/P86 onto the 
structures of APT1 and APT2, we can see that these residues flank the lower active site-
capping loop, as shown in Figure 6. The residues in this region probably affect the 
conformation dynamics of this loop, and possibly the accessibility of substrates or 
inhibitors into the active site.  We hypothesize that perhaps the P86 and L78 residues on 
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APT2 together confer more rigidity to the active site-capping loop. As ML348 is 
predicted to have more rotational degrees of freedom than ML349 due to its greater 
number of freely rotating bonds, perhaps the binding of ML348 the a more rigid active 
site as hypothesized in APT2 would be disfavored due to entropic reasons. Nevertheless, 
more studies need to be done to validate this hypothesis.  
Figure 7: Depiction of the active site of APT1 and APT2 along with their isoform-specific inhibitors 
docked in the active site. Residues that were mutated are shown in stick representations and labeled. (A) 
ML348 docked in the active site of APT1. (B) ML349 docked in the active site of APT2 
 
2. Characterizing ML349 inhibitor derivatives: What defines the active site? 
Individual contributions. As described before, I am thankful to Christina 
Rodriguez, Laura Rodriguez and Michael Won who performed most of the bacterial 
transformations and protein purifications to obtain WT and mutant APTs for study. Dr. 
Jaimeen Majmudar, Michael Won and Andrea Chong synthesized the various ML349 
derivatives that were probed. Michael Won and Dr. Dahvid Davda provided much 
advice and direction for this project, and Dr. Dahvid Davda aided significantly with the 
data analysis and generation of figures. Primarily, my principal investigator, Dr. Brent 
Martin, conceived the main idea for this project, provided funding and gave direction on 
the experiments that were conducted. My role was to optimize the conditions for the 
E F
Q83
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L176
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A B 
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assays, perform dose-response assays and thermal stability assays, perform initial 
analysis of the data, and write up this chapter.  
  
Background. In addition to probing residues that determine specificity of the active site, 
we wanted to further characterize the steric and electronic requirements for binding the 
active site of APT1 and APT2. One hypothesis derived from the crystal structure of 
APT2 with ML349 was that ML349 binding was partially due to its sulfone group (not 
found in ML348), which mimicked the tetrahedral intermediate of the transition state 
when associating with the catalytic serine hydroxyl. To test this, we synthesized two 
ML349 derivatives with increasingly reduced groups on the sulfone moiety, termed 
ML349-sulfoxide and ML349-thioether. The reasoning behind this is that if the oxygen 
atoms of the sulfone moiety were critical in hydrogen bonding with the catalytic serine 
to mimic the transition state, then removal of those oxygen atoms should abrogate 
binding of ML349 to APT2.  
 Further, if formation of a tetrahedral intermediate-like structure plays a key role 
in the binding of ML349 to APT2, then a catalytically dead APT2-S122A in which the 
catalytic serine is mutated to an alanine that can no longer hydrogen bond should have 
show a reduced Tm shift compared to WT APT2 when bound to ML349. The 
contribution of the sulfone-catalytic serine interaction towards stabilizing ML349 
binding to APT2 could not be assayed using the substrate-based hydrolysis of ResOAc 
as the S122A has no catalytic activity and cannot hydrolyze ResOAc. Thus, we plan to 
use the thermal stability assay to probe this interaction.  
 At the same time, we also wanted to characterize the binding of the opposite end 
of ML349, as the crystal structure of ML349 bound to the APT2 active site suggests that 
this region may lie in the hydrophobic channel in APT2 that dictates ligand specificity. 
	   17	  
To test this, we synthesized various ML349 derivatives, referred to as the methoxy 
series, with the substitution of various groups of differing length, size and polarity. The 
full list of compounds tested, along with their Ki values for both APT1 and APT2 is 
included at the end of this section in Supplementary Figure 1.  
 Results and Discussion. We first used steady-state inhibitor dose-dependence 
assays to determine the contribution of the sulfone moiety to the binding of ML349 to 
APT2. Indeed, the removal of the first oxygen atom from the sulfone group increases the 
Ki of ML349 for APT2 drastically by almost 20 fold (105.30 nM for ML349, 2222.35 
nM for ML349-sulfoxide). This suggests the critical importance of both oxygens at the 
sulfone moiety, as ML349-sulfoxide was added as a racemic mixture, and if only one of 
either oxygen atom would suffice, then the transition from sulfone to sulfoxide would 
only result in a small 2-3 fold increase in Ki, unlike the 20-fold increase observed. The 
removal of the second oxygen atom further increases the Ki of the ML349-thioether 
above the detectable level of our assay (> 10,000 nM), as shown in Figure 8 below, 
further iterating the importance of the sulfone moiety.  
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Figure 8: Ki values for ML349 derivatives of the sulfone moiety and the methoxy group. The 
compounds in the first row depict the sulfone and methoxy regions of the lead APT2 inhibitor, ML349.   
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 The results of the thermal stability assay of APT2 with ML349 and the reduced 
thioether derivative support our results as the thioether derivative showed no significant 
thermal stabilization of APT2, as shown in Figure 9A below. Surprisingly, the APT2-
S122A mutant, which lacks the catalytic serine hydroxyl group that putatively binds the 
ML349 sulfone, shows a comparable Tm shift when treated with ML349 compared to 
APT2-WT, as shown in Figure 9B below. This implies that ML349 is still able to form 
stabilizing interactions with APT2-S122A even without the sulfone-serine hydroxyl 
interactions. It might be that the stabilization of the sulfone group of ML349 is not only 
coordinated by the catalytic serine, but also other polar residues in that region, which 
would be thus be drastically abrogated should any of the sulfone oxygens be removed.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Thermal stabilization assay results for ML349 derivatives. (A) Tm of APT2-WT with ML349 
and ML349-thioether. (B) Tm of APT2-WT and APT2-S122A against ML349. (C) Tm of APT2-WT 
against the ML349 methoxy derivatives.  
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We also used the inhibitor dose-dependence assays to obtain Ki values for the 
methoxy series of ML349 derivatives. Interestingly, when we compared the affinity of 
APT2 for derivatives with longer, aliphatic ethoxy or O-alkynyl substitutions with that 
for ML349, we don’t see an appreciable difference in Ki values, as seen in Figure 8 
above. On the other hand, when we substituted the methoxy group on ML349 with the 
shorter methyl and hydroxyl groups, we see that the affinity of APT2 for these 
compounds is much weakened. This suggests that perhaps APT2 favors long aliphatic 
substrates to facilitate interaction with its hydrophobic surfaces. When we compared this 
result to that obtained using the thermal stability assay, we observe that the Tm shifts of 
APT2 were not significantly different between the ethoxy, alkynyl, methyl and unaltered 
ML349, suggesting that the contribution of these groups towards the binding of APT2 is 
comparable to each other, as seen in Figure 9C.  
Interestingly, the inhibitor dose-response assay showed that several compounds 
in the ML349 methoxy series also showed affinity for both APT1-WT and APT2-WT. 
These compounds include the alkynyl, acetyl and desmethoxy derivatives of ML349, 
and were termed ML349 dual inhibitors (Supplementary Figure1). However, when we 
assayed these compounds using the thermal stability assay against APT1-WT and 
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APT2-WT, the results suggest that the dual inhibitors affect both enzymes via different 
mechanisms. As seen in Figure 10A, the dual inhibitors have a destabilizing effect on 
APT1-WT, whereas Figure 10B shows that the same compounds have a stabilizing 
effect on APT2-WT. We hypothesize that in the case of APT1, the compound may be 
binding the active site in such a way that perturbs the tight packing of the enzyme, 
allowing solvent access to the protein core, thus destabilizing the enzyme. On the other 
hand, the stabilization of APT2 by the same compounds implies that inhibition is 
achieved by enthalpic stabilization of the protein-ligand complex by the compounds, 
thus competing with the substrate for access to the active site. However, this is just our 
initial hypothesis and further experiments need to be conducted to determine how the 
previously APT2 isoform-selective ML349 gained affinity for APT1 merely through 
substitutions in the methoxy group. 
In summary, we have shown that the highly oxidized sulfone group of ML349 
plays a critical role in selectively binding the active site of APT2, possibly through 
hydrogen bonding and the formation of a mimic of the transition state tetrahedral 
intermediate. We have also shown that the methoxy group of ML349 is likely a key 
determinant of its enzyme selectivity, as substitutions of this group can cause the 
compound to gain potency towards APT1. We also hypothesize that the long 
hydrophobic channel leading to the APT2 catalytic site may predispose APT2 towards 
longer, aliphatic substrates, due to the enzyme’s affinity for ML349 with longer 
hydrophobic groups substituted at the methoxy position. However, further experiments 
using native substrates are necessary to further probe the active site of APT2. One future 
direction for this project would be to test the dose-dependence of APT1 and APT2 
against fatty acids of different lengths and degrees of saturation in order to identify the 
possible native substrates of these enzymes.  
	   21	  
Supplementary Figure 1: List of Ki values for ML348, ML349 as well as methoxy, sulfone, and 
biotinylated derivatives of ML349 against APT1, APT2 and APT1-I75L. 
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